Medicare, Medicaid and HSA/FSA GLP-1 Coverage: What to Check in 2026

Government drug coverage is not a single yes-or-no rule. The medication, diagnosis, benefit pathway and date matter. Guidance that only says Medicare excludes weight-loss drugs misses the temporary GLP-1 Bridge now available to eligible beneficiaries. Guidance that says all Medicare members qualify goes too far in the other direction.

This page was substantively revised October 16, 2026 using current CMS and Medicare information. Coverage and program terms can change. Ask the prescriber and plan to verify your situation before making a financial commitment.

Medicare GLP-1 Bridge: current dates and cost

CMS says the Medicare GLP-1 Bridge runs from July 1, 2026 through December 31, 2027. Eligible beneficiaries pay a $50 copay for drugs furnished through the program. It is a temporary demonstration, not a promise of permanent coverage after that date¹.

The Bridge operates outside the usual Part D payment flow. CMS states that the Part D deductible does not apply, the copay does not count toward true out-of-pocket costs, and low-income subsidy assistance does not reduce that program copay¹. Ask which pathway is processing your prescription before comparing a Bridge price with a standard Part D estimate.

A commercial savings card is a separate arrangement. Do not assume its advertised price or restrictions describe the Bridge. Our Wegovy pill cost guide distinguishes the manufacturer's commercial savings offer, self-pay prices and Medicare questions.

Who might qualify?

Medicare's current patient guidance requires eligible drug coverage and clinical criteria. It lists different BMI thresholds with specified associated conditions, and it explains the prescriber's role in prior authorization². Having a Medicare card or wanting treatment is not enough to establish eligibility.

Use the current Medicare eligibility information with your clinician rather than guessing from a diagnosis name. Accurate records matter. Do not omit a condition or relabel a prescription's purpose to fit a different benefit pathway.

Medicare currently lists Wegovy injection or tablets, Foundayo tablets and Zepbound KwikPen for the Bridge. It explicitly distinguishes the KwikPen from single-dose Zepbound vials or pens². Do not treat a different formulation, an off-label prescription or a compounded preparation as automatically covered by this list.

Coverage for another approved indication is a separate question

A drug used for diabetes or another covered indication may be evaluated through a different pathway from weight-management treatment. Medicare's patient guidance distinguishes those circumstances². A clinician needs to identify the actual medical use and the plan's requirements.

A prescription is not a coverage approval. Ask the plan which product is on formulary, whether prior authorization applies, which documents are needed and which pharmacies can fill it. Request the expected out-of-pocket amount after the relevant claim or authorization is evaluated.

Our prior-authorization guide explains common questions about documentation and denials. If approval is denied, request the written reason and appeal process rather than assuming that switching to a different brand name will solve the problem.

Medicaid: check your state and managed-care plan

Federal Medicaid law permits exclusion of agents used for weight loss, but that permission does not mean every state applies an identical exclusion. State coverage policies and clinical criteria must be checked for the specific drug and intended use³.

Look at the current state formulary and, where relevant, the managed-care plan's rules. Ask whether the drug is covered for your diagnosis, whether prior authorization is needed and which prescribers or pharmacies can participate. A commercial insurance list on a telehealth website does not establish Medicaid participation.

For Medicaid members under 21, ask about Early and Periodic Screening, Diagnostic, and Treatment, or EPSDT. CMS explains that medically necessary coverable services can be required even when they are outside the state's usual benefit list, with medical necessity assessed case by case⁴. This is a reason to seek an appropriate evaluation, not a guarantee that every requested obesity prescription must be approved.

HSA and FSA funds address a different question

Insurance coverage and eligibility for tax-advantaged reimbursement are separate. IRS guidance distinguishes treatment of a physician-diagnosed disease, including obesity, from weight-loss spending solely for appearance or general well-being⁵.

Ask your plan administrator what documentation is needed for the prescription and any separate care fees. A program advertising HSA or FSA payment does not establish that every membership component qualifies. Keep itemized receipts and avoid treating meals, supplements or general fitness purchases as automatically eligible because they accompany treatment.

Do not claim the same expense twice through reimbursement and a tax deduction. Individual circumstances and plan rules matter. A benefits administrator or tax professional can explain the appropriate treatment of your particular expenses; this article does not calculate personal tax savings.

What to ask before paying a telehealth service

Confirm whether the service accepts your coverage, provides prior-authorization support and dispenses the covered formulation through an eligible pharmacy. Ask which fees remain due if the prescription is declined, authorization is denied or the pharmacy cannot fill it.

Separate the care charge from the medication charge. A $50 program copay does not automatically include an unrelated telehealth subscription. Request the full invoice, minimum term and cancellation rules before authorizing recurring payments.

Our provider-selection guide covers licensure and follow-up checks, and provider reviews compare published service terms. If coverage is unavailable, the cash-pay guide explains other pricing questions. The research library links the clinical and practical evidence behind related decisions.